Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE HeartWare International, Inc.
FRAMINGHAM, Mass., Oct. 25, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended September 30, 2013, at 8:00 a.m. U.S. Eastern Standard Time on Thursday, November 7, 2013. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the third quarter and business outlook. The call may be accessed by dialing 1-877-941-8418 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-480-629-9809.
A live webcast of the call will also be available in the Investor section at the Company's website (http://ir.heartware.com/). A replay of the conference call will be available through the above weblink immediately following completion of the call.
A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 35 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market.
HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.
For further information:
HeartWare International, Inc.
Phone: +1 508 739 0864
©2012 PR Newswire. All Rights Reserved.